Attached files
| file | filename |
|---|---|
| EX-99.1 - EXHIBIT 99.1 - Amarantus Bioscience Holdings, Inc. | v415981_ex99-1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 22, 2015
AMARANTUS BIOSCIENCE HOLDINGS, INC.
(Exact name of registrant as specified in its charter)
| Nevada | 000-55016 | 26-0690857 |
| (State or other jurisdiction of incorporation or organization) | (Commission File Number) |
IRS Employer Identification No.) |
|
655 Montgomery Street, Suite 900 San Francisco, CA |
94111 |
| (Address of Principal Executive Offices) | (Zip Code) |
(408) 737-2734
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ Written communications pursuant to Rule 425 under the Securities Act
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
| Item 8.01 | Other Items. |
On July 22, 2015, Amarantus Bioscience Holdings, Inc. (the “Company”) issued a press release announcing positive results on the accuracy of the LymPro Test®, its blood-based diagnostic assay for Alzheimer's disease (AD), to discriminate between subjects with clinically diagnosed AD versus healthy controls at the Alzheimer’s Association International Conference® (AAIC) being held July 18-23, 2015, in Washington, DC.
A copy of the Company’s press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
| Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits
| Exhibit No. | Description | |
|
99.1
|
Amarantus Bioscience Holdings, Inc. Press Release, dated July 22, 2015.
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| AMARANTUS BIOSCIENCE HOLDINGS, INC. | ||
| Date: July 22, 2015 | By: | /s/ Gerald E. Commissiong |
| Name: Gerald E. Commissiong | ||
| Title: Chief Executive Officer | ||